Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CL stock price vs PACB: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PACB's multiple
Needs PACB P/E.
Implied fair value · at CL's multiple
Needs Annual EPS is negative.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
COLGATE-PALMOLIVE COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Pacific Biosciences of California, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PROCTER & GAMBLE Co
CL vs PG
JOHNSON & JOHNSON
CL vs JNJ
CHURCH & DWIGHT CO INC /DE/
CL vs CHD
KIMBERLY CLARK CORP
CL vs KMB
EDGEWELL PERSONAL CARE Co
CL vs EPC
UNILEVER PLC
CL vs UL
ILLUMINA, INC.
CL vs ILMN
THERMO FISHER SCIENTIFIC INC.
CL vs TMO
AGILENT TECHNOLOGIES, INC.
CL vs A
DANAHER CORP /DE/
CL vs DHR
REVVITY, INC.
CL vs RVTY
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CL can sustain its 16.2% operating margin and justify a premium multiple despite only 1.4% revenue growth, then hold or accumulate on pullbacks; otherwise, the provided valuation framework points to downside because the current price of $92.11 is above the $69.11 implied price and well above the low-end DCF range.
On the provided P/S framework, CL’s current price of $92.11 implies 25.0% downside to $69.11, which is essentially the same as PACB-implied range of $69.22. The gap appears driven more by valuation methodology than by a clean operating mismatch, since PACB has materially weaker fundamentals but a higher EV/Revenue multiple.
Supporting Metrics
